Clinical Trial Update: PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating first-line gastric cancer treatment with a PD-1/TGF-β bispecific agent SHR-1701 in combination with SHR2554 or Apatinib plus c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Apatinib (apatinib)
• SHR-1701
• SHR2554

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: Advanced Gastric Cancer, SHR1701 | Phase 2 | Status: RECRUITING